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(P<0.05), and treatment-related toxicity was not observed in 
the pancreas and kidneys while slight glomerulopathy was 
detected. 
The pharmacokinetic, imaging, and therapy studies suggest 
that the theranostic twins(68Ga/177Lu)-labeled bombesin 
derivatives have promising characteristics for application in 
nuclear medicine, namely, for the diagnosis and treatment of 
GRPR-overexpressing prostate tumors. 
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Hypothesis: Radiation fibrosis (RF) effects up to 70% of 
patients who have undergone radiotherapy.  It is 
characterized by irreversible scarring of normal tissue 
resulting in functional morbidity and increased risk of 
surgical complications. Adipose-derived stromal cells (ADSCs) 
are a subcategory of mesenchymal stromal cell. Much of the 
therapeutic benefit of ADSCs has been attributed to secretion 
of cytokines and growth factors involved in 
immunomodulation, cell survival, and metabolism. We 
hypothesize that ADSCs may be therapeutically effective for 
RF through reversal of metabolic aberrations. 
Methods: A mouse model of RF was developed and ADSC 
isolation was confirmed by surface marker expression and by 
differentiation capacity down the mesenchymal lineage. GFP 
and luciferase labelled ADSCs were used to assess 
biodistribution and cell survival after transplantation. To 
determine the therapeutic effect of ADSC transplantation for 
RF, we assessed functional changes to tissue elasticity using a 
leg contracture measurement tool and to collagen deposition 
using trichrome blue staining. To determine the mechanism 
of ADSC-mediated fibrosis reversal, we assessed 
transcriptomic changes to RF tissue.  
Results: A RF model was created by radiating the hind limb of 
C3H mice. This model showed a dose dependent leg 
contracture and histological findings of fibrosis. We 
confirmed the immunophenotype of isolated ADSC and their 
ability to differentiate into adipogenic, chondrogenic, and 
osteogenic lineages. ADSC transplantation showed a 
statistically significant trend towards improved leg 
contracture (2-way ANOVA, p<0.05) and reduced collagen 
deposition. Biodistribution studies confirmed the presence of 
ADSCs in the subdermis of RF tissue with persistence for at 
least 18 days post-transplantation.  Preliminary RNA-seq 
over-representation pathway analysis showed that lipid 
metabolism and PPARG signaling were among the top 
pathways down regulated in radiation fibrosis and was 
partially reversed with ADSC treatment. ADSCs directly 
reversed alterations to lipid metabolism in radiated 
fibroblasts through indirect co-culture.  
Conclusions: ADSC transplantation may be an effective 
treatment for the reversal of radiation fibrosis through 
metabolic reprogramming. As cancer survivorship increases, 
the prevalence of radiation fibrosis will rise and necessitate 
increased focus on effective treatment strategies for this 
condition.   
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Purpose: The detection of gamma rays for monitoring 
purposes can overcome some of the limitations of PET, since 
they are more abundant than positron emitters and are 
produced within nanoseconds after irradiations. However, 
their continuous emission spectrum up to high energies (more 
than 10 MeV) make their detection challenging [1]. 
Collimated systems and Compton cameras are being 
developed for this application. 
The IRIS group of the Instituto de Fisica Corpuscular (IFIC-
CSIC/UVEG, Valencia) has developed a three-layer Compton 
telescope based on LaBr3 scintillator crystals for hadron 
therapy monitoring within the ENVISION project.   
Materials and Methods: The telescope consists of three planes 
of LaBr3 crystals, which provide high energy resolution and 
fast response, coupled to silicon photomultiplier arrays. A 
custom made data acquisition system has been developed to 
read out the detectors and operate them in time 
coincidence, employing the VATA64HDR16 ASIC[2]. The 
system aims at combining two- and three-layer events in 
order to profit from the high efficiency of the former and the 
high precision of the latter. The functionality of the device 
has been tested in the laboratory with radioactive sources, 
and also in beam tests. A dedicated image reconstruction ML-
EM code has also been developed for both types of events. 
Results: The system has been characterized in the laboratory 
acquiring data with radioactive sources of different energies. 
The detector response in terms of linearity, uniformity and 
spatial, energy and timing resolution has been obtained for 
the three layers, improving the results of the first tests. In 
addition, images of a point-like Na-22 source have been 
reconstructed with two and three-layer systems. The 
preliminary spatial resolution obtained is 7.3 mm FWHM with 
the two-layer system and 8.6 mm FWHM with the three-layer 
system.  
The two-layer system has also been tested in a proton beam 
at KVI-CART, Groningen. Data were taken with a 150 MeV 
proton beam with an intensity of about 108 protons/s and a 
lateral beam spread of 5.3 mm impinging on a PMMA 
phantom. The PMMA target was placed in two different 
positions along the beam separated by 10 mm. The data 
analysis and image reconstruction of the data have shown a 
difference in the reconstructed profile consistent with the 
phantom position [3]. 
Conclusions: The laboratory tests carried out assess the 
correct functioning of the device. In-beam results show the 
capability of detecting range shifts. Current work is focused 
on performance improvement of the system and on 
simultaneous operation of two and three detector layers. 
Further tests in beam are planned at HZDR Dresden for 
December 2015. 
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Purpose: Monte Carlo (MC) codes are widely used in the 
hadrontherapy community due to their detailed description 
of radiation transport and interaction with matter. In this 
work, we present the latest developments and applications 
of the FLUKA Monte Carlo code [1,2].   
Material/methods: MC methods are being utilized at several 
institutions for a wide range of activities spanning from beam 
characterization to quality assurance and 
dosimetric/radiobiological studies. The suitability of a MC 
code for application to hadrontherapy demands accurate and 
reliable physical models for the description of the transport 
and the interaction of all components of the expected 
radiation field. This becomes extremely important to 
correctly perform not only physical but also biological dose 
calculations. In addition, accurate prediction of emerging 
secondary radiation is of utmost importance in emerging 
areas of research aiming at in-vivo treatment verification.  
Results: Validations and applications at several experimental 
sites as well as proton/ion therapy facilities with active beam 
delivery systems will be presented:  
• Physical database generation: laterally integrated 
depth-dose profiles, lateral-dose distributions at 
different depths, secondary fragment yields and 
fragment energy spectra at different depths.  
• Forward MC re-calculations of physical/RBE-
weighted dose distributions of proton and carbon 
ion treatment plans.  
• MC-based treatment planning for proton and heavy 
ions beam therapy. 
• Studies for introducing new ions (4He and 16O) in 
the clinical practice.  
Conclusions: FLUKA's flexibility and the satisfactory 
agreements with several dosimetric data and nuclear 
fragment yields demonstrate that the code is a valuable and 
powerful support for the hadrontherapy community.  
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Purpose: Conventionally, intensity modulated particle 
therapy (IMPT) fields are optimized independently of the 
fractionation scheme. Following some precursory works [1—
3], this study aims at investigating whether the application of 
spatial and temporal modulations in fractionation patterns, 
which involve the delivery of daily inhomogeneous fractional 
dose (IFD) distributions, may increase the therapeutic gain. 
Materials/Methods: We simulated the irradiation of different 
clinical cases with different ions (1H, 4He, 12C) and we carried 
out a comparison between two types of treatment plans. 
These were: (1) a conventional plan with a standard 
fractionation scheme in which each beam irradiates the 
whole planning target volume (PTV) delivering a uniform dose 
of 2 Gy per fraction; (2) an alternative plan that implies IFD 
distributions, delivering homogeneous dose to distinct regions 
of the PTV in different fractions. Each field was weighted to 
minimize its contribution to the proximal region of the PTV, 
so to limit the dose excursion in the surrounding normal 
tissues and obtain different local fractionation schemes in 
the volumes of interest. The comparison was based on the 
evaluation of the tumor complication probability (TCP) and 
normal tissue complication probability (NTCP). We evaluated 
these quantities following the approach proposed by Kallman 
et al. [4], based on the Linear-Quadratic-Poisson model. We 
considered a variable relative biological effectiveness (RBE) 
and the impact of the variable linear energy transfer (LET) 
distributions on the sensitivity to the time structure of the 
irradiation. 
Results: For the considered cases, the comparison showed 
that the IFD-based approach leads to an improvement of the 
therapeutic index with respect to the standard approach (+6-
10%). The extent of the gain is dependent, among other 
factors, on the sensitivity of the tissues to the employed ion 
radiation. Some critical issues were identified related to the 
choice of weights and spatial configurations of the fields. 
Conclusions: This work investigates the possibility to improve 
the therapeutic index by delivering temporally and spatially 
heterogeneous dose distributions in the PTV, following the 
IFD paradigm. A methodology has been found which has 
proven to be successful in the considered clinical cases. 
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In Particle Therapy, cancer treatments are performed using 
accelerated charged particles whose high irradiation 
precision and conformity allows the tumor destruction while 
sparing the surrounding healthy tissues. Dose release 
monitoring devices using photons and charged particles 
produced by the beam interaction with the patient body have 
already been proposed, but no attempt based on the 
detection of the abundant secondary radiation neutron 
component has been made yet. The reduced attenuation 
length of neutrons yields a secondary particle sample that is 
larger in number when compared to photons and charged 
particles. Furthermore, neutrons allow for a backtracking of 
the emission point that is not affected by multiple scattering. 
Since neutrons can release a significant dose far away from 
the tumor region, a precise measurement of their flux, 
production energy and angle distributions is eagerly needed 
